Houston First Corp. will sponsor the Aira technology at several venues across the city so that the blind and vision impaired can enjoy each area. Photo by Micahl Wycoff

A partnership between the Houston First Corporation and Aira, an app that helps blind and low-vision people gain independence by navigating tasks and public spaces, is now live at venues around the city.

Houston First will cover the costs of use for the app in its venues, including the George R. Brown Convention Center, Avenida Houston, Wortham Theater Center, and Jesse H. Jones Hall for the Performing Arts. The organization has plans to expand to the Miller Outdoor Theatre, said John Gonzalez, senior vice president of operations and general manager for Houston First.

"Technology is changing the experiences users have at our events," Gonzalez said. "We want to make our venues as accessible as possible."

California-based Aira's role in offering a vessel for facilities to be more accessible to low-vision and blind Houstonians is groundbreaking, said Vince Morvillo, an account executive with Aira who is blind.

"This technology is as important to a blind person as it is to a sighted person," Morvillo said. "You, as a person with sight, have the opportunity to look, to see things, to interact with people. When you're blind, you're not out and about; you don't have too many people to interact with. The ability to be able to go and do something when you choose to do so is really important."

The app essentially creates sight on demand. Users can use the Aira app on their smartphones and be connected to a trained operator, who will help them navigate the scene around them using video being fed to the app through their phone. The operators will then guide the user to their destination or even help them with everyday necessities like grocery shopping.

"The blind world needs this," Morvillo said. "This technology gets blind people out in the world. Businesses know how successful they are by how many people support them. I just don't understand why blind people are an untapped resource. Nobody's out there trying to get the blind shopper."

In addition to the blind population, Morvillo says that this will also help the aging population, who may often struggle with their vision later in life, and will increase accessibility options around the city.

Aira and Houston First's efforts to increase accessibility for patrons are now being recognized nationally. The National Federation of the Blind recently announced it would be bringing its annual convention to Houston in 2020.

"We are thrilled to host the group and are committed to providing a safe and enjoyable experience for all visitors," Houston First said in an email to InnovationMap. "It is our goal that Houston First venues provide an entertaining and immersive experience for all guests, and our partnership with Aira puts us one step closer to achieving that goal."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."